Selinexor for Pediatric Solid Tumors or Brain Tumors

"Due to the limited information available on this pharmacological study, it received a score of 1 in terms of safety efficacy. This is indicative that we are currently at Phase 1 trial stage."

"This trial is not currently looking for participants; the posting was published on October 5th, 2015 and its most recent update occurred on October 7th, 2022. If you are searching for other trials, there are presently 5594 active glioma studies and 48 Pharmacological Studies with enrollment available to patients."

"In order to fit the criteria of this medical trial, patients must be between 12 months and 21 years old."

"Since 2014, research on Pharmacological Study has been ongoing. Karyopharm Therapeutics Inc initially sponsored the initial investigation which was conducted in that year and involved 16 participants. After Phase 1 drug approval had been established, 48 trials began to take place internationally spanning 28 different countries with a collective 259 sites of study."

"This medical trial is open to 68 individuals with glioma aged between 12 Months and 21. Eligible patients must comply with the following parameters: Part B: Patients displaying recurrent or refractory high-grade glioma (WHO grade III/IV) not mandating surgical resection, that have had histological authentication of their malignancy at initial diagnosis or relapse; neurological conditions in people suffering from CNS tumors should be stable for a minimum duration of 7 days before enrolment; paralysis preventing walking, but permitting wheelchair use will still qualify as ambulatory regarding performance score assessment criteria.Part A: Recurrent/refractory"

"The Pharmacological Study was first conducted in 2014 at Children's Healthcare of Atlanta and has since completed 201 trials. Currently, 48 studies are ongoing with the majority located in Memphis, Tennessee."

"This clinical trial is no longer in the recruitment phase, with its last update on October 7th 2022. However, if you are looking for alternative studies, there are currently 5594 research projects recruiting patients diagnosed with glioma and 48 Pharmacological Studies that are accepting participants."

"Over a two-day period, this trial seeks to measure the maximum serum concentration of selinexor as its primary outcome. As secondary objectives, researchers aim to ascertain antitumor effects, pharmacodynamics in HGG patients, and radiographic response by study part schema and dose level."

"This clinical trial is recruiting patients from Saint Jude's Children Research Hospital in Memphis, the Children's Hospital of Los Angeles and Lurie Childrens' Hospital-Chicago. Moreover, there are 20 other sites offering enrollment into this study."